Methotrexate: An active drug in bladder cancer
نویسندگان
چکیده
منابع مشابه
Methotrexate--the anchor drug--an introduction.
School of Medicine, New York, USA: 3Rheumazentrum Ruhrgebiet, St. Josefs Krankenhaus, Herne, Germany. Theodore Pincus, MD Bruce Cronstein, MD Jürgen Braun, MD Please address correspondence and reprint requests to: Theodore Pincus, MD, NYU Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003, USA. E-mail: [email protected] Received and accepted on August 2, 2010. Clin Exp Rheu...
متن کاملActive surveillance for nonmuscle invasive bladder cancer
Nonmuscle invasive bladder cancer (NMIBC) is known to be a heterogeneous malignancy that requires varying treatment modalities and follow-up schedules. Low-grade Ta papillary tumors are categorized as low-risk NMIBC because of their favorable prognosis. There is an expanding movement that overdiagnosis and overtreatment should be avoided considering the economic impact and the patients' quality...
متن کاملDocetaxel: overview of an active drug for breast cancer.
Docetaxel and paclitaxel differ in their precise molecular targets and pharmacokinetics. Docetaxel is more avidly taken up by tumor cell lines than paclitaxel, and its efflux is slower. Comparative cytotoxicity data suggest greater potency. These factors may help explain the clinical differences that have been observed between the taxanes in patients with breast cancer.
متن کاملMicroRNAs as biomarkers associated with bladder cancer
Bladder cancer is the fifth most common cancer with significant morbidity and mortality. Recently, numerous studies demonstrated that microRNAs are emerging as diagnostic biomarkers for bladder cancer. Specific miRNA profiles have been identified for several samples from patients with bladder cancer. MicroRNAs are noncoding RNA molecules of approximately 23 nucleotides that play important roles...
متن کاملDifferent stages in drug development for muscle-invasive bladder cancer
Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease. Despite optimal therapy, half of the patients will succumb to disease. This prognosis could not be improved over the last three decades. Therefore, MIBC is left behind from other cancers such as prostate, where novel treatment options were discovered and improve patient outcomes. While being aware of the recent emerging evide...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1981
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(19810315)47:6<1246::aid-cncr2820470603>3.0.co;2-g